

NEWS RELEASE

Sunstone announce new corporate structure and brand names

Copenhagen, 21 February 2019 – Sunstone Capital today announce that the two investment arms of Sunstone – Life Science Ventures and Technology Ventures – in the future will operate under the names Sunstone Life Science Ventures (<https://sunstone.eu>) and Heartcore Capital, respectively. See also separate announcement from Heartcore Capital (<https://medium.com/@heartcorecap/introducing-heartcore-capital-europes-consumer-only-vc-341341915409>). This is a natural further development of our activities and reflects the increased specialization of venture capital investment within the two sectors – ICT and Life Science. This calls for sharpening of the profiles and investment strategies of the two investment arms, which is best accomplished under different brand names.

This news release follows the recent announcements of first closing of Sunstone Life Science Ventures Fund IV (“Sunstone LSV IV”) at €80 million and a further expansion of the investment team. The investment strategy of the new fund is a continuation of Sunstone Life Science Ventures’ successful strategy of investing in novel therapeutics with the potential to improve the quality of patient care and treatment.

The Sunstone Life Science Ventures investment team consists of Søren Lemonius, Managing General Partner; Peter Benson, Chairman & General Partner; Dr Sten Verland, General Partner and Dr Claus Andersson, General Partner with the recent addition of Dr Jacob Lange Moresco, Investment Director. All experienced venture capital professionals with previous industry background and access to an extensive network of industry experts and scientific leaders.

About Sunstone Life Science Ventures:

Sunstone Life Science Ventures is an independent European venture capital investment firm founded in 2007 by an international team of industry experts with combined entrepreneurial, operational and financial experience. Sunstone Life Science Ventures focuses on developing and expanding early-stage Life Science companies with strong potential to achieve global success in their markets. Since the inception, Sunstone Life Science Ventures has invested in more than 40 companies in the areas of pharmaceuticals, medical technologies and diagnostics, and has completed more than 20 successful IPOs and large M&A transactions. Managing total funds of approx. €500 million, Sunstone Life Science Ventures is one of the largest European venture capital investors.

Sunstone contacts:

Søren Lemonius
Managing General Partner
+45 40 81 48 89
lemonius@sunstone.eu

Peter Benson
Chairman & General Partner
+45 40 80 48 69
benson@sunstone.eu

Sten Verland, PhD MSc
General Partner
+45 24 22 19 69
verland@sunstone.eu

Claus Andersson, PhD
General Partner
+45 22 70 50 65
andersson@sunstone.eu

Sunstone Life Science Ventures A/S - Lautrupsgade 7, 2 - DK-2100 Copenhagen, Denmark
<http://sunstone.eu>